C2i Genomics Expands AI-Powered Cancer Detection and Monitoring Capabilities in US and China Through Partnership with NuProbe

October 13, 2021

The deal will combine C2i’s AI-driven cancer intelligence platform with NuProbe’s advanced sequencing technology to power pharma and diagnostic services

NEW YORK — October 13, 2021 — C2i Genomics, a cancer intelligence company, today announced its technology co-development and expansion into China via a strategic partnership with NuProbe Global, a genomics and molecular diagnostics company specializing in ultrasensitive sequencing panels. The strategic alliance will power high-impact pharmaceutical and diagnostic services, leveraging C2i Genomics’ artificial intelligence (AI)-powered cancer intelligence platform across NuProbe’s chemistry products and sequencing networks in both China and the United States.

Four million people in China are diagnosed with cancer every year. In 2020, the country accounted for 30% of all cancer-related deaths worldwide. China is one of the world’s fastest-growing genomics markets, but despite the power of sequencing technology for diagnosis, disease monitoring and precision treatment, only 5% of China’s cancer cases are sequenced.

As part of this collaboration, NuProbe and C2i will engage in the co-development of chemistry and software products that will expand the traditional whole-genome library preparation to include additional signal enrichment for cancer hotspots, Microsatellite instability (MSI) and fusions. The combined whole-genome signal integration and ultra-sensitive interception of cancer hotspots, MSI and fusions will significantly improve cancer screening and molecular residual disease (MRD) monitoring clinical performance. The combined products will be commercialized for pharma and diagnostic services in China through the NuProbe sequencing lab network and for the rest of the world through NuProbe’s chemistry kit and C2i’s cloud-based cancer intelligence platform. 

“C2i Genomics’ advanced cloud platform and state-of-the-art algorithms provide great synergy to NuProbe’s ultra-sensitive sequencing technology,” said David Zhang, co-founder and General Manager of NuProbe USA. “Combining the unique capabilities of both companies will provide a new technology and simplified workflow for more precise cancer screening and monitoring, access to greater insights and potential to develop therapies that mirror the dynamics of cancer.”

“C2i is built on the foundations of innovation, breaking global boundaries and changing the status quo of cancer management and we found NuProbe to be a natural partner to our vision of technology innovation and global product expansion,” explained Asaf Zviran, co-founder and CEO of C2i Genomics. “Together, we’re setting a new standard for cancer diagnosis, research and care, globally.” 

The partnership is the latest in a series of solid milestones from C2i, advancing its mission to scale its AI-powered cancer detection platform globally. This year, C2i announced a network collaboration with Premier Inc. and began its expansion into Southeast Asia through its partnership with NovogeneAIT. The company recently boosted its leadership team, welcoming Glenn Pomerantz MD, JD as Chief Medical Officer (CMO) and two strategic hires across business development and data science. 

For companies interested in deploying the C2-Intelligence Platform, please visit www.c2i-genomics.com

About C2i Genomics 

Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to provide up to 100x more sensitive detection than competing liquid biopsy companies. With a headquarters in NYC, CLIA lab in Cambridge, MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. For more information, please visit www.c2i-genomics.com

About NuProbe Global

NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe’s vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.

Media Contact

Rachel Reed
NuProbe
+1 715-240-0797
rachel.reed@nuprobe.com

    Request A Quote









    X
    Share via
    Copy link
    Powered by Social Snap